0001562180-24-005566.txt : 20240703
0001562180-24-005566.hdr.sgml : 20240703
20240703075520
ACCESSION NUMBER: 0001562180-24-005566
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240703
DATE AS OF CHANGE: 20240703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KARABELAS ARGERIS N
CENTRAL INDEX KEY: 0001191229
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 241098263
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 471851754
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2024-07-01
false
0001590877
REGENXBIO Inc.
RGNX
0001191229
KARABELAS ARGERIS N
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
true
false
false
false
true
Common Stock
2024-07-01
4
M
false
10000.00
3.76
A
21286.00
D
Common Stock
2024-07-01
4
S
false
10000.00
11.2691
D
11286.00
D
Stock Options (Right to Buy)
3.76
2024-07-01
4
M
false
10000.00
0.00
D
2025-05-18
Common Stock
10000.00
30000.00
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $10.98 to $11.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide
upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 24 months thereafter.
/s/ Patrick J. Christmas as attorney-in-fact
2024-07-03